These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38027155)

  • 1. Original delayed-start ovarian stimulation protocol with a gonadotropin-releasing hormone antagonist, medroxyprogesterone acetate, and high-dose gonadotropin for poor responders and patients with poor-quality embryos.
    Takeuchi K; Orita Y; Iwakawa T; Kuwatsuru Y; Kuroki Y; Fukumoto Y; Mizobe Y; Tokudome M; Moewaki H
    Front Endocrinol (Lausanne); 2023; 14():1277873. PubMed ID: 38027155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.
    Beguería R; García D; Vassena R; Rodríguez A
    Hum Reprod; 2019 May; 34(5):872-880. PubMed ID: 30927417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations.
    Zhou R; Dong M; Huang L; Wang S; Fan L; Liang X; Zhang X; Liu F
    Front Endocrinol (Lausanne); 2023; 14():1117513. PubMed ID: 37143731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.
    Giles J; Alama P; Gamiz P; Vidal C; Badia P; Pellicer A; Bosch E
    Fertil Steril; 2021 Aug; 116(2):404-412. PubMed ID: 33814126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of letrozole co-treatment during ovarian stimulation on oocyte yield, embryo development, and live birth rate in women with normal ovarian reserve: secondary outcomes from the RIOT trial.
    Bülow NS; Warzecha AK; Nielsen MV; Andersen CY; Holt MD; Petersen MR; Sopa N; Zedeler A; Englund AL; Pinborg A; Grøndahl ML; Skouby SO; Macklon NS
    Hum Reprod; 2023 Nov; 38(11):2154-2165. PubMed ID: 37699851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle.
    Glujovsky D; Pesce R; Miguens M; Sueldo C; Ciapponi A
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD013827. PubMed ID: 38032057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles.
    Tandulwadkar S; Gupta S; Singh A; Mishra S; Singhania S
    JBRA Assist Reprod; 2023 Mar; 27(1):15-19. PubMed ID: 35621299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles.
    Martinez F; Clua E; Roca M; Garcia S; Polyzos NP
    Hum Reprod; 2022 Nov; 37(12):2777-2786. PubMed ID: 36269092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology.
    Yildiz S; Turkgeldi E; Angun B; Eraslan A; Urman B; Ata B
    Fertil Steril; 2019 Oct; 112(4):677-683. PubMed ID: 31371053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial.
    Ashrafi M; Arabipoor A; Yahyaei A; Zolfaghari Z; Ghaffari F
    Reprod Biol Endocrinol; 2018 Dec; 16(1):124. PubMed ID: 30593268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual trigger with the combination of gonadotropin-releasing hormone agonist and standard dose of human chorionic gonadotropin improves
    Mutlu I; Demirdag E; Cevher F; Erdem A; Erdem M
    J Obstet Gynaecol; 2022 Jul; 42(5):1239-1244. PubMed ID: 34565274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
    Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
    Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
    [No Abstract]   [Full Text] [Related]  

  • 14. Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders.
    Liu Y; Su R; Wu Y
    Front Endocrinol (Lausanne); 2020; 11():605939. PubMed ID: 33519714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed Gonadotropin-Releasing Hormone Antagonist Protocol
    Dong M; Sun L; Huang L; Wang F; Zhang X; Liu F
    Front Endocrinol (Lausanne); 2021; 12():690575. PubMed ID: 34867773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medroxyprogesterone acetate used in ovarian stimulation is associated with reduced mature oocyte retrieval and blastocyst development: a matched cohort study of 825 freeze-all IVF cycles.
    Ozgur K; Berkkanoglu M; Bulut H; Donmez L; Coetzee K
    J Assist Reprod Genet; 2020 Sep; 37(9):2337-2345. PubMed ID: 32696289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation.
    Kamath MS; Maheshwari A; Bhattacharya S; Lor KY; Gibreel A
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008528. PubMed ID: 29096046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders.
    Moffat R; Hansali C; Schoetzau A; Ahler A; Gobrecht U; Beutler S; Raggi A; Sartorius G; De Geyter C
    Hum Reprod; 2021 Mar; 36(4):987-997. PubMed ID: 33367742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.
    Cakmak H; Tran ND; Zamah AM; Cedars MI; Rosen MP
    Fertil Steril; 2014 May; 101(5):1308-14. PubMed ID: 24636401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen valerate pretreatment with the antagonist protocol does not increase oocyte retrieval in patients with low ovarian response: a randomized controlled trial.
    Zhang S; Tang Y; Wang X; Zong Y; Li X; Cai S; Ma H; Guo H; Song J; Lin G; Lu G; Gong F
    Hum Reprod; 2022 Jun; 37(7):1431-1439. PubMed ID: 35460400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.